Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin.

ABSTRACT: COVID-19 pathophysiology is caused by a cascade of respiratory and multiorgan failures arising, at least in part, from the SARS-CoV-2-driven dysregulation of the master transcriptional factor STAT3. Pharmacological correction of STAT3 over-stimulation, which is at the root of acute respiratory distress syndrome (ARDS) and coagulopathy/thrombosis events, should be considered for treatment of severe COVID-19. In this perspective, we first review the current body of knowledge on the role of STAT3 in the pathogenesis of severe COVID-19. We then exemplify the potential clinical value of treating COVID-19 disease with STAT3 inhibitors by presenting the outcomes of two hospitalized patients with active cancer and COVID-19 receiving oral Legalon^®-a nutraceutical containing the naturally

SUBMITTER: Bosch-Barrera J 

PROVIDER: S-EPMC8778965 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature